Posted on November 10th, 2008 by
Results from Oncotype DX® affect treatment decisions in a large portion of breast cancer patients who undergo the test. These results were recently published in the American Journal of Surgery.
Although chemotherapy is recommended for many women with early-stage, node-negative breast cancer, the benefit of chemotherapy varies. Identifying in advance those women who are most likely to benefit from chemotherapy may allow for more individualized treatment. This would allow women who are unlikely to benefit from chemotherapy to avoid the toxic effects of treatment. Oncotype DX is covered by several large health coverage policies.
Oncotype DX is a genomic test that predicts the likelihood of a cancer recurrence, the likelihood of benefit from chemotherapy, and the likelihood of survival in patients with newly diagnosed breast cancer that has not spread to their lymph nodes (node-negative) and is estrogen receptor (ER)-positive. ®®Oncotype DX evaluates the activity of 21 genes from a sample of the patient®s cancer to determine the patient®s Recurrence Score. The Recurrence Score ranges from 0 to 100, with a higher score indicating a greater risk of recurrence. Oncotype DX is covered by several large health coverage policies and has been added to medical guidelines for early-stage breast cancer.
Results from recent studies have also indicated that Oncotype DX accurately determines hormone-receptor status and human epidermal growth factor (HER)-2 status among women with early breast cancer.
Researchers from New York recently conducted a study to evaluate the rate at which results of Oncotype DX actually change treatment decisions among women with early breast cancer. This study included the evaluation of data from 85 women with ER-positive, node-negative breast cancer who had undergone testing with Oncotype DX. Forty-four percent of patients changed their treatment decisions based upon results of Oncotype DX.
The researchers concluded that results from Oncotype DX significantly affect treatment decisions in a large portion of patients with ER-positive, node-negative breast cancer.
Patients with early breast cancer may wish to speak with their physician regarding their individual risks and benefits of testing with Oncotype DX.
Reference: Asad J, Jacobson A, Estabrook A, et al. Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer® American Journal of Surgery. 2008;196:527-529.
Copyright © 2010 CancerConsultants Breast Cancer Information Center. All Rights Reserved.
You must be logged-in to the site to post a comment.